Challenges of phase III trial design for novel treatments in diseases with no standard treatment

The AZA-001 myelodysplasia study model

Pierre Fenaux, John F. Seymour, Valeria Santini, Lew Silverman, Steven Gore, Alan List, Guillermo Sanz, Ghulam J. Mufti, Eli Estey, Arlene S. Swern, C. L. Beach, Eva Hellstrom-Lindberg

Research output: Contribution to journalArticle

Abstract

For cancers lacking standard treatments, comparing new agents with existing treatments is problematic. Here we discuss the study design from the AZA-001 trial, which compared azacitidine with 3 frequently used conventional care regimens (CCR) for higher-risk myelodysplastic syndromes. Before randomization, physicians preselected the most appropriate of 3 CCR for each patient, after thorough examination. Patients were then randomized to azacitidine or CCR. Patients randomized to CCR received their preselected treatment, thus including patients otherwise excluded as poor candidates for a single comparator. This design may serve as a template in other cancers lacking standard therapy.

Original languageEnglish (US)
Pages (from-to)258-262
Number of pages5
JournalLeukemia Research
Volume38
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Azacitidine
Myelodysplastic Syndromes
Therapeutics
Random Allocation
Neoplasms
Physicians

Keywords

  • Azacitidine
  • CCR
  • Heterogenous
  • Novel treatment
  • Standard
  • Study design

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology
  • Medicine(all)

Cite this

Challenges of phase III trial design for novel treatments in diseases with no standard treatment : The AZA-001 myelodysplasia study model. / Fenaux, Pierre; Seymour, John F.; Santini, Valeria; Silverman, Lew; Gore, Steven; List, Alan; Sanz, Guillermo; Mufti, Ghulam J.; Estey, Eli; Swern, Arlene S.; Beach, C. L.; Hellstrom-Lindberg, Eva.

In: Leukemia Research, Vol. 38, No. 2, 02.2014, p. 258-262.

Research output: Contribution to journalArticle

Fenaux, P, Seymour, JF, Santini, V, Silverman, L, Gore, S, List, A, Sanz, G, Mufti, GJ, Estey, E, Swern, AS, Beach, CL & Hellstrom-Lindberg, E 2014, 'Challenges of phase III trial design for novel treatments in diseases with no standard treatment: The AZA-001 myelodysplasia study model', Leukemia Research, vol. 38, no. 2, pp. 258-262. https://doi.org/10.1016/j.leukres.2013.10.014
Fenaux, Pierre ; Seymour, John F. ; Santini, Valeria ; Silverman, Lew ; Gore, Steven ; List, Alan ; Sanz, Guillermo ; Mufti, Ghulam J. ; Estey, Eli ; Swern, Arlene S. ; Beach, C. L. ; Hellstrom-Lindberg, Eva. / Challenges of phase III trial design for novel treatments in diseases with no standard treatment : The AZA-001 myelodysplasia study model. In: Leukemia Research. 2014 ; Vol. 38, No. 2. pp. 258-262.
@article{712641fb27ce4f97bb52769a73aa3d0c,
title = "Challenges of phase III trial design for novel treatments in diseases with no standard treatment: The AZA-001 myelodysplasia study model",
abstract = "For cancers lacking standard treatments, comparing new agents with existing treatments is problematic. Here we discuss the study design from the AZA-001 trial, which compared azacitidine with 3 frequently used conventional care regimens (CCR) for higher-risk myelodysplastic syndromes. Before randomization, physicians preselected the most appropriate of 3 CCR for each patient, after thorough examination. Patients were then randomized to azacitidine or CCR. Patients randomized to CCR received their preselected treatment, thus including patients otherwise excluded as poor candidates for a single comparator. This design may serve as a template in other cancers lacking standard therapy.",
keywords = "Azacitidine, CCR, Heterogenous, Novel treatment, Standard, Study design",
author = "Pierre Fenaux and Seymour, {John F.} and Valeria Santini and Lew Silverman and Steven Gore and Alan List and Guillermo Sanz and Mufti, {Ghulam J.} and Eli Estey and Swern, {Arlene S.} and Beach, {C. L.} and Eva Hellstrom-Lindberg",
year = "2014",
month = "2",
doi = "10.1016/j.leukres.2013.10.014",
language = "English (US)",
volume = "38",
pages = "258--262",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Challenges of phase III trial design for novel treatments in diseases with no standard treatment

T2 - The AZA-001 myelodysplasia study model

AU - Fenaux, Pierre

AU - Seymour, John F.

AU - Santini, Valeria

AU - Silverman, Lew

AU - Gore, Steven

AU - List, Alan

AU - Sanz, Guillermo

AU - Mufti, Ghulam J.

AU - Estey, Eli

AU - Swern, Arlene S.

AU - Beach, C. L.

AU - Hellstrom-Lindberg, Eva

PY - 2014/2

Y1 - 2014/2

N2 - For cancers lacking standard treatments, comparing new agents with existing treatments is problematic. Here we discuss the study design from the AZA-001 trial, which compared azacitidine with 3 frequently used conventional care regimens (CCR) for higher-risk myelodysplastic syndromes. Before randomization, physicians preselected the most appropriate of 3 CCR for each patient, after thorough examination. Patients were then randomized to azacitidine or CCR. Patients randomized to CCR received their preselected treatment, thus including patients otherwise excluded as poor candidates for a single comparator. This design may serve as a template in other cancers lacking standard therapy.

AB - For cancers lacking standard treatments, comparing new agents with existing treatments is problematic. Here we discuss the study design from the AZA-001 trial, which compared azacitidine with 3 frequently used conventional care regimens (CCR) for higher-risk myelodysplastic syndromes. Before randomization, physicians preselected the most appropriate of 3 CCR for each patient, after thorough examination. Patients were then randomized to azacitidine or CCR. Patients randomized to CCR received their preselected treatment, thus including patients otherwise excluded as poor candidates for a single comparator. This design may serve as a template in other cancers lacking standard therapy.

KW - Azacitidine

KW - CCR

KW - Heterogenous

KW - Novel treatment

KW - Standard

KW - Study design

UR - http://www.scopus.com/inward/record.url?scp=84892490159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892490159&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2013.10.014

DO - 10.1016/j.leukres.2013.10.014

M3 - Article

VL - 38

SP - 258

EP - 262

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 2

ER -